To be introduced in Finance Bill 2016
Mix of in-house active and passive
Fixed interest allocation hurt returns
New co-operation with Turquoise
Research analyst also appointed
NAV down 7.8% over the year
The Merchants trust's Simon Gergel explains why investing in one of the UK's biggest healthcare stocks - GlaxoSmithKline - is not as simple as many investors envisage